Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT)

Aaltje Y. Adema,Maarten A. de Jong,Martin H. de Borst,Pieter M. ter Wee,Marc G. Vervloet

Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT)

2016

Aaltje Y. Adema
Maarten A. de Jong
Martin H. de Borst
Pieter M. ter Wee
Marc G. Vervloet

Background: Increased levels of phosphate and fibroblast growth factor-23 (FGF23) are strong predictors of cardiovascular morbidity and mortality in patients with

Keywords:

Vitamin D and neurology
Fibroblast growth factor 23
Endocrinology
Diabetes mellitus
Left ventricular hypertrophy
Internal medicine
Fibroblast
Kidney disease
Fibroblast growth factor
Sevelamer
Medicine
Phosphate

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations